Yükleniyor... / Loading...
This study evaluates the drug PF-03084014 (a gamma secretase inhibitor) in patients with advanced cancer or acute T-cell leukemia/lymphoblastic lymphoma resistant to standard therapy. It included patients over 16. It was a Phase 1 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available * Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available * Men and women \>16 years old Exclusion Criteria: * Prior treatment with a gamma secretase inhibitor for treatment of cancer * Patients taking Tamoxifen * Patients with active graft versus host disease * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness * Patients who are pregnant or breast feeding * Patients with clinical evidence of central nervous system disease